Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Receivables (2024 - 2025)

CG Oncology's Change in Receivables history spans 2 years, with the latest figure at $301000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 53.26% year-over-year to $301000.0; the TTM value through Dec 2025 reached $320000.0, changed N/A, while the annual FY2025 figure was $320000.0, 53.56% down from the prior year.
  • Change in Receivables reached $301000.0 in Q4 2025 per CGON's latest filing, up from $238000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $644000.0 in Q4 2024 to a low of -$436000.0 in Q1 2025.